Last reviewed · How we verify
NCT05036954: EYEBRID
Observational Study on the Efficacy and Tolerance of EYEBRID Lenses
trial testing EyeBrid Excel hybrid lenses in Contact Lens Complication in 60 participants. Status unknown.
30 November 2021
Quick facts
| Lead sponsor | University Hospital, Caen |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 60 |
| Start date | 30 September 2021 |
| Primary completion | 30 November 2021 |
| Estimated completion | 30 July 2022 |
| Sites | 1 location across France |
Drugs / interventions tested
- EyeBrid Excel hybrid lenses
Conditions studied
- Contact Lens Complication — all drugs for Contact Lens Complication →
Sponsor
University Hospital, Caen
Who can join
Adults 18 to 80, any sex, with Contact Lens Complication. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Technical advances in lenses are continuous and materials are improved. We provide a prospective longitudinal observational study evaluating the efficacy and safety of new EyeBrid Excel hybrid lenses (LCS) in the treatment of severe ametropia and for patients with corneal irregularities. This study should include 60 patients for a period of three months. The aim of this work is to assess the improvement in the best corrected visual acuity and the good tolerance of this lens.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05036954
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Contact Lens Complication
Currently open trials in the same condition.
- NCT06650306 — The Impact of Soft Contact Lenses on the Corneal Neuromediators and Optical Quality in High Myopia Prior to SMILE · recruiting
Other University Hospital, Caen trials
Trials by the same sponsor.
- NCT07406737 — Feasibility and Outcomes Registry of Lumenless dEfibrillation Leads for Conduction System Pacing · not yet recruiting
- NCT06639750 — Respiratory Microbioma and Respiratory Complications After Hematopoietic Stem Cell Transplantion · not yet recruiting
- NCT07467031 — Bachstim Registry: a Feasability Study of Bachmann's Area Pacing · not yet recruiting
- NCT07477132 — A Dose-response Study to Determine the Right Dosage of Sugammadex as a Reversal Agent of Rocuronium in Infants Between 1 · Phase 4 · not yet recruiting
- NCT07520578 — EFFECTIVENESS OF EARLY INFORMATION AND ENDORSMENT BY GP TO INCREASE COLONOSCOPY FOLLOW-UP AND REDUCE DELAYS IN PEOPLE WI · Phase 3 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05036954 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Caen
- Last refreshed: 8 September 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05036954.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing